By Suherman Candra Maholtra 
The administration of the shingles vaccine to patients already living with established heart disease is associated with a nearly 50% reduction in the risk of major cardiovascular complications within one year of inoculation, according to a landmark study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26). The research, which analyzed a massive cohort of nearly a quarter-million American adults, suggests that the preventive benefits of the herpes zoster vaccine extend far beyond the dermatological and neurological protection it was originally designed to provide. By mitigating the systemic inflammation and clotting risks associated with shingles flare-ups, the vaccine appears to serve as a potent tool in the secondary prevention of heart attacks, strokes, and heart failure.
The Intersection of Viral Infection and Cardiovascular Risk
For decades, the medical community has recognized a complex relationship between viral infections and acute cardiovascular events. Atherosclerotic cardiovascular disease (ASCVD), characterized by the buildup of fats, cholesterol, and other substances in and on the artery walls, creates a state of chronic low-grade inflammation. When a person experiences an acute infection—such as influenza, pneumonia, or shingles—this inflammation can escalate rapidly, leading to the destabilization of arterial plaques.
Shingles, or herpes zoster, occurs when the varicella-zoster virus, the same virus that causes chickenpox, reactivates in the body after lying dormant for years in the nerve tissue. While the most visible symptom is a painful skin rash, the biological impact is systemic. Previous clinical observations have noted that shingles infections can trigger a cascade of pro-thrombotic activity, increasing the likelihood of blood clots forming near the heart or brain. This study confirms that for those with pre-existing heart disease, the stakes of such a reactivation are exceptionally high, and the protection offered by vaccination is commensurately significant.
Methodology and Scope of the TriNetX Study
To quantify the cardioprotective effects of the vaccine, lead author Robert Nguyen, MD, a resident physician at the University of California, Riverside, and his team utilized TriNetX, a global federated health research network. This database provides access to de-identified electronic health records (EHRs) from millions of patients across the United States, allowing for a robust statistical analysis of real-world clinical outcomes.
The researchers identified 246,822 adults aged 50 and older who had been diagnosed with atherosclerotic heart disease between 2018 and 2025. The cohort was divided into two equal groups of 123,411 individuals. The first group had received at least one dose of either Shingrix (the recombinant zoster vaccine) or Zostavax (the older live-attenuated vaccine), while the second group remained unvaccinated. To ensure the integrity of the comparison, researchers employed propensity score matching, adjusting for demographics, socioeconomic factors—including housing stability, employment, and education—and comorbid conditions such as diabetes, hypertension, and chronic kidney disease.
The primary focus of the analysis was the occurrence of major adverse cardiac events (MACE) and all-cause mortality during the window of one month to one year following vaccination. By excluding the first 30 days post-vaccination, the researchers sought to eliminate any immediate confounding variables related to the procedure itself, focusing instead on the sustained protective window.
Dramatic Reductions in Mortality and Cardiac Complications
The findings presented at ACC.26 revealed a striking disparity in outcomes between the vaccinated and unvaccinated cohorts. Patients who received the shingles vaccine were 46% less likely to experience a major adverse cardiac event compared to their unvaccinated counterparts. Even more significant was the impact on survival; the vaccinated group saw a 66% reduction in the risk of death from any cause during the one-year follow-up period.
The granular data further highlighted the vaccine’s broad impact on various facets of cardiovascular health:
- Heart Attack (Myocardial Infarction): The risk was reduced by 32%.
- Stroke: Vaccinated individuals saw a 25% lower incidence of cerebrovascular accidents.
- Heart Failure: The risk of new or worsening heart failure dropped by 25%.
Dr. Nguyen emphasized the magnitude of these figures, noting that the level of risk reduction observed in this study is comparable to the benefits achieved through major lifestyle interventions, such as smoking cessation or the consistent use of high-intensity statin therapy. For a population already at high risk due to existing plaque buildup, these percentages represent thousands of lives potentially saved and a significant reduction in the burden on the healthcare system.
The Biological Mechanism: Why the Vaccine Protects the Heart
The protective effect of the shingles vaccine likely stems from its ability to prevent the acute inflammatory surge that accompanies a viral reactivation. When the herpes zoster virus becomes active, it travels along the nerves to the skin, but it also causes inflammation in the walls of the blood vessels (vasculopathy). This inflammation can cause the fibrous cap of an atherosclerotic plaque to rupture. Once a plaque ruptures, the body’s clotting mechanism is triggered to "heal" the area, which can result in a total blockage of the artery, leading to a heart attack or stroke.
Furthermore, shingles has been linked to transient increases in blood pressure and a higher state of hypercoagulability. By preventing the viral flare-up entirely, or at least reducing its severity, the vaccine prevents these physiological stressors from occurring. Dr. Nguyen noted that while the general public benefits from the vaccine, the "cardioprotective effects might be even greater" among those with existing disease, as their cardiovascular systems are already more vulnerable to the destabilizing effects of systemic inflammation.
Chronology of Shingles Vaccination Policy
The evolution of shingles vaccination in the United States provides important context for this study. For years, Zostavax was the primary option, though its efficacy waned over time. In 2017, the FDA approved Shingrix, a non-live, recombinant vaccine that demonstrated over 90% efficacy in preventing shingles and postherpetic neuralgia. Following this, the Centers for Disease Control and Prevention (CDC) updated its recommendations, favoring Shingrix for adults 50 and older.
This study’s timeframe (2018–2025) coincides with the widespread adoption of Shingrix. The data suggests that as vaccination rates have increased, the secondary benefits to the heart have become more apparent. This research adds to a growing body of evidence, including a 2025 study which found a 23% reduction in cardiovascular events among generally healthy adults, suggesting that the vaccine’s benefits are durable and potentially last up to eight years.
Addressing Vaccine Hesitancy and Public Health Implications
Despite the clear benefits, vaccine hesitancy remains a hurdle in public health. Dr. Nguyen acknowledged that in an era often characterized by medical disinformation, patients are frequently skeptical of new or additional vaccinations. However, he argued that framing the shingles vaccine not just as a way to avoid a painful rash, but as a critical component of heart health, could change the conversation in clinical settings.
"Vaccines are one of the most important medicines we have to prevent disease," Dr. Nguyen stated. These results provide cardiologists and primary care physicians with a powerful new talking point: getting vaccinated for shingles may be just as important for the heart as taking a daily aspirin or managing cholesterol.
Medical experts not involved in the study have noted that these findings could lead to a shift in clinical guidelines. If further long-term studies confirm these results, the shingles vaccine could eventually be categorized alongside the influenza and pneumococcal vaccines as a standard recommendation for all patients with coronary artery disease, regardless of their perceived risk of shingles.
Limitations and Future Research Directions
While the study’s sample size is robust, the researchers acknowledged certain limitations inherent in observational data. The "healthy user bias" is a primary concern—individuals who choose to get vaccinated may be more health-conscious in general, more likely to adhere to medication regimens, and more likely to seek regular medical follow-ups.
Although the team adjusted for numerous socioeconomic factors and health behaviors, it is difficult to completely isolate the vaccine’s effect from other positive health choices. Additionally, the current analysis only tracks outcomes for one year. As heart disease is a lifelong condition, understanding the long-term trajectory of this protection is essential. Future research will likely focus on whether booster shots are necessary to maintain cardioprotective benefits and whether the vaccine offers similar protection against other inflammatory-driven conditions, such as vascular dementia.
Conclusion: A New Pillar of Cardiovascular Care
The presentation of this research at ACC.26 marks a significant moment in the integration of infectious disease prevention and cardiology. As Dr. Robert Nguyen prepares to present his full findings—titled "Herpes Zoster Vaccination and Risk of Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease"—to his peers in San Antonio, the medical community is bracing for a potential shift in how preventive care is delivered to heart patients.
With a 46% reduction in major cardiac events and a 66% reduction in all-cause mortality, the shingles vaccine has emerged as a surprisingly effective intervention for some of the most vulnerable patients in the healthcare system. For those living with the daily reality of heart disease, a simple two-dose vaccine series may offer a vital shield against the unpredictable and often devastating impact of viral-induced cardiac complications.
